Chronic Lymphocytic Leukemia

FDA Approves Revolutionary Oral Combination Therapy for Chronic Lymphocytic Leukemia, Offering Patients Freedom from Long-Term Treatment

Post author:Bree Clare
Post published:March 5, 2026
Post category:Chronic Lymphocytic Leukemia

AbbVie has announced a landmark regulatory milestone with the US FDA's approval of a supplemental new drug application (sNDA) for the combination of Venclexta (venetoclax) and acalabrutinib as a first-line…

New Genomic Insights Reveal Unique CLL Patterns in African American Patients

Post author:Bree Clare
Post published:October 2, 2025
Post category:Chronic Lymphocytic Leukemia

Recent research has brought to light striking genetic differences in chronic lymphocytic leukemia (CLL) among African American (AA) patients, suggesting that their disease may follow a distinct course compared to…

source: shutterstock.com

Jaypirca Now Approved for Adults with CLL or SLL

Post author:Jessica Lynn
Post published:December 26, 2023
Post category:Chronic Lymphocytic Leukemia small lymphocytic lymphoma

In January 2023, the U.S. FDA approved Jaypirca (pirtobrutinib) for the treatment of adults with relapsed or refractory mantle cell lymphoma who had previously undergone two lines of systemic…

source: shutterstock.com

After 15 Years, Life-Changing Results for this Chronic Lymphocytic Leukemia Patient

Post author:James Moore
Post published:October 16, 2023
Post category:Chronic Lymphocytic Leukemia

Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…

Fotocitizen / Pixabay

Rare Community Profiles: Dr. Brian Koffman Discusses the Complexities of Immunization for People with CLL/SLL

Post author:Jessica Lynn
Post published:October 10, 2023
Post category:Chronic Lymphocytic Leukemia Chronic Lympocytic Leukemia small lymphocytic lymphoma

Rare Community Profiles Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families,…

Glofitamab with Obinutuzumab Shows Promise in Heavily Pretreated Richter Syndrome

Post author:Jessica Lynn
Post published:September 7, 2023
Post category:Chronic Lymphocytic Leukemia Richter syndrome

Also known as Richter’s Transformation, Richter syndrome is a rare and aggressive complication of chronic lymphocytic leukemia (CLL). When someone develops Richter syndrome, their CLL can transform into another rare…

source: pixabay.com

Study of the Week: Exercise Provides Major Benefits in Chronic Lymphocytic Leukemia

Post author:James Moore
Post published:September 5, 2023
Post category:Chronic Lymphocytic Leukemia

Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…

source: shutterstock.com

Making a Major Impact on B Cell Cancers

Post author:Rose Duesterwald
Post published:September 1, 2023
Post category:Chronic Lymphocytic Leukemia Diffuse Large B-cell Lymphoma Follicular lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma small lymphocytic lymphoma Waldenstrom Macroglobulinemia

Accutar Biotechnology, Cranbury, New Jersey recently announced via BioSpace that dosing has begun with the first patient enrolled in the Phase 1 trial of AC0676 a chimeric degrader molecule…

source: shutterstock.com

Study Highlights Benefits of Exercise for Chronic Lymphocytic Leukemia

Post author:James Moore
Post published:August 30, 2023
Post category:Chronic Lymphocytic Leukemia

According to a story from Medpage Today, a study conducted by scientists at the University of Texas MD Anderson Cancer Center highlighted the substantial benefits of aerobic exercise in people…

PDPics / Pixabay

First Patient Dosed in MB-106 Trial for NHL, CLL

Post author:Jessica Lynn
Post published:October 17, 2022
Post category:Chronic Lymphocytic Leukemia Non-Hodgkin lymphoma Non-Hodgkin's Lymphoma Waldenstrom Macroglobulinemia

At the start of October 2022, biopharmaceutical company Mustang Bio, Inc. shared via news release that the first patient was treated in a study of MB-106. Within the study,…

source: pixabay.com

Zanubrutinib Superior to Ibrutinib in Advanced CLL

Post author:Rose Duesterwald
Post published:July 14, 2022
Post category:Chronic Lymphocytic Leukemia small lymphocytic lymphoma

The most common form of leukemia in Western countries is chronic lymphocytic leukemia (CLL). The disease accounts for almost thirty percent of known leukemia cases. Approximately 30,000 Europeans were…

Pexels / Pixabay

Positive Data Available on NX-2127 for CLL

Post author:Jessica Lynn
Post published:June 6, 2022
Post category:Chronic Lymphocytic Leukemia

On May 26, 2022, biopharmaceutical company Nurix Therapeutics, Inc. ("Nurix") shared via news release that positive data was available from an ongoing Phase 1a dose escalation study. Within the study,…

source: pixabay.com

New Study Data on NVG-111 for MCL and CLL

Post author:Kendall Mason
Post published:June 6, 2022
Post category:Chronic Lymphocytic Leukemia Mantle Cell Lymphoma

According to a press release that can be found on AP News, new data have been released on a potential treatment - called NVG-111 - for both mantle cell lymphoma…

DIY: A Pulmonary Hypertension Patient Drains His Lungs at Home

Post author:Rose Duesterwald
Post published:March 30, 2022
Post category:Chronic Lymphocytic Leukemia small lymphocytic lymphoma

Roger Bliss, 68-year-old pulmonary hypertension (PH) patient, was diagnosed with chronic lymphocytic leukemia and small lymphocytic lymphoma. In addition, Roger has celiac disease. He recently interviewed with Pulmonary Hypertension News.…

Approval of CLL Therapy is Being Reevaluated by FDA Following Safety Concerns

Post author:Trudy Horsting
Post published:March 2, 2022
Post category:Chronic Lymphocytic Leukemia Non-Hodgkin's Lymphoma

The FDA has just announced that they are reevaluating their approvals for Ukoniq. This reevaluation comes after study findings which demonstrated there may be an increased risk of fatality for…

Trial Uncovers That Age Doesn’t Independently Impact Chronic Lymphocytic Leukemia Outcomes

Post author:Trudy Horsting
Post published:March 1, 2022
Post category:Chronic Lymphocytic Leukemia

A recent study examined the impact of age on clinical outcomes for patients diagnosed with chronic lymphocytic leukemia (CLL). This study was published in the journal Blood Advances. All patients in…

source: pixabay.com

SEQUOIA Trial Results Show Remarkable Response Rate in High-Risk CLL Subgroup

Post author:Rose Duesterwald
Post published:February 4, 2022
Post category:Chronic Lymphocytic Leukemia small lymphocytic lymphoma

Targeted Oncology recently featured a discussion by Dr. Jennifer Brown, director of Dana Farber’s Chronic Lymphocytic Leukemia Center, on the interim results from the SEQUOIA Phase 3 trial. The trial…

Chronic Lymphocytic Leukemia Patients Need Both Molecular And Clinical Risk Assessments

Post author:Trudy Horsting
Post published:December 15, 2021
Post category:Chronic Lymphocytic Leukemia

Dr. Deborah M. Stephens from the Huntsman Cancer Institute recently presented at the 39th Annual Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow (CFS). The presentation surrounded how critical identifying…

Study Shows Novel BTK Degrader Has Meaningful Results for Patients with Chronic Lymphocytic Leukemia

Post author:Alyssa Stevens
Post published:November 11, 2021
Post category:Chronic Lymphocytic Leukemia

According to a recent article, a study looking at an investigational BTK degrader proved to have important results in patients with chronic lymphocytic leukemia. Chronic Lymphocytic Leukemia (CLL) Chronic lymphocytic…

Source: Pixabay.com

LAVA-051 for CLL Earns Orphan Drug Designation

Post author:Jessica Lynn
Post published:October 22, 2021
Post category:Chronic Lymphocytic Leukemia

According to a news release from biotechnology company LAVA Therapeutics N.V. ("LAVA"), the company's therapeutic candidate LAVA-051 recently earned Orphan Drug designation from the FDA. The therapy is designed for…

Photo by Paweł Czerwiński on Unsplash

Pirtobrutinib Shows Promise for Previously Treated CLL, SLL

Post author:Jessica Lynn
Post published:October 11, 2021
Post category:Chronic Lymphocytic Leukemia small lymphocytic lymphoma

The 2021 Society for Hematological Oncology (SOHO) Annual Meeting took place last month from September 8-11, 2021. During the meeting, researchers discussed new advances in the field of hematology. According…

source: pixabay.com

BTK Inhibitors in Chronic Lymphocytic Leukemia are an Emerging Therapy

Post author:Trudy Horsting
Post published:August 31, 2021
Post category:Chronic Lymphocytic Leukemia

Meghan Thompson, a doctor and 3rd year fellow at Memorial Sloan Kettering Cancer Center has recently explained all of the emerging treatments using BTK inhibitors to treat CLL, chronic lymphocytic…

Photo by Jude Beck on Unsplash

Study: What is the QOL for CLL Patients and Their Caregivers?

Post author:Kendall Mason
Post published:July 28, 2021
Post category:Chronic Lymphocytic Leukemia

Having a rare, chronic disease can impact one's life significantly, whether it's physically, spiritually, socially, or psychologically. Not only this, but those responsible for these patients' care are affected as…

fernandozhiminaicela / Pixabay

New Protein Markers Discovered for Chronic Lymphocytic Leukemia

Post author:Kendall Mason
Post published:July 27, 2021
Post category:Chronic Lymphocytic Leukemia

A better comprehension of one's cancer can provide improved treatment outcomes. It's easier to fight something that one understands. That's why a recent article published in Medical Xpress is so…

FDA Receives Biologics License Application for Combination Treatment for CLL

Post author:Kendall Mason
Post published:April 29, 2021
Post category:Chronic Lymphocytic Leukemia

TG Therapeutics has been developing ublituximab as a treatment for chronic lymphocytic leukemia (CLL) when used in combination with umbralisib, marketed as UKONIQ. The biopharmaceutical company has recently completed and…

FDA Approves Revolutionary Oral Combination Therapy for Chronic Lymphocytic Leukemia, Offering Patients Freedom from Long-Term Treatment

New Genomic Insights Reveal Unique CLL Patterns in African American Patients

Jaypirca Now Approved for Adults with CLL or SLL

After 15 Years, Life-Changing Results for this Chronic Lymphocytic Leukemia Patient

Rare Community Profiles: Dr. Brian Koffman Discusses the Complexities of Immunization for People with CLL/SLL

Glofitamab with Obinutuzumab Shows Promise in Heavily Pretreated Richter Syndrome

Study of the Week: Exercise Provides Major Benefits in Chronic Lymphocytic Leukemia

Making a Major Impact on B Cell Cancers

Study Highlights Benefits of Exercise for Chronic Lymphocytic Leukemia

First Patient Dosed in MB-106 Trial for NHL, CLL

Zanubrutinib Superior to Ibrutinib in Advanced CLL

Positive Data Available on NX-2127 for CLL

New Study Data on NVG-111 for MCL and CLL

DIY: A Pulmonary Hypertension Patient Drains His Lungs at Home

Approval of CLL Therapy is Being Reevaluated by FDA Following Safety Concerns

Trial Uncovers That Age Doesn’t Independently Impact Chronic Lymphocytic Leukemia Outcomes

SEQUOIA Trial Results Show Remarkable Response Rate in High-Risk CLL Subgroup

Chronic Lymphocytic Leukemia Patients Need Both Molecular And Clinical Risk Assessments

Study Shows Novel BTK Degrader Has Meaningful Results for Patients with Chronic Lymphocytic Leukemia

LAVA-051 for CLL Earns Orphan Drug Designation

Pirtobrutinib Shows Promise for Previously Treated CLL, SLL

BTK Inhibitors in Chronic Lymphocytic Leukemia are an Emerging Therapy

Study: What is the QOL for CLL Patients and Their Caregivers?

New Protein Markers Discovered for Chronic Lymphocytic Leukemia

FDA Receives Biologics License Application for Combination Treatment for CLL

Let’s Work Together!

Keep Up to Date

Learn More